Silence Therapeutics plc is a biotechnology business based in the UK. Silence Therapeutics shares (SLN.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Silence Therapeutics employs 46 staff and has a trailing 12-month revenue of around £1.4 million.
|Latest market close||N/Ap|
|52-week range||330p - 570p|
|50-day moving average||498.8788p|
|200-day moving average||451.2128p|
|Wall St. target price||277p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-25.3p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||£1.4 million|
|Gross profit TTM||£-13,092,000|
|Return on assets TTM||-26.15%|
|Return on equity TTM||-81.78%|
|Market capitalisation||£466.5 million|
TTM: trailing 12 months
We're not expecting Silence Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Silence Therapeutics's shares were split on a 1:50 basis on 30 April 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Silence Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Silence Therapeutics shares which in turn could have impacted Silence Therapeutics's share price.
Over the last 12 months, Silence Therapeutics's shares have ranged in value from as little as 330p up to 570p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Silence Therapeutics's is 1.2952. This would suggest that Silence Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various product candidates, including SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein; and SLN500 for the treatment of complement-mediated diseases. Silence Therapeutics plc has a strategic collaboration with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and collaboration with Genomics England Limited. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.